Comparative Pharmacology
Head-to-head clinical analysis: JENTADUETO XR versus SITAGLIPTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENTADUETO XR versus SITAGLIPTIN.
JENTADUETO XR vs SITAGLIPTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JENTADUETO XR combines linagliptin, a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP) leading to glucose-dependent insulin secretion and decreased glucagon release, and metformin, an AMPK activator that decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and improves insulin sensitivity.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases active incretin (GLP-1 and GIP) levels by preventing their degradation, thereby enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner.
The usual starting dose of JENTADUETO XR (empagliflozin/metformin extended-release) is 5 mg/1000 mg orally once daily with the evening meal. Dose can be increased to a maximum of 12.5 mg/2000 mg once daily based on glycemic control and tolerability.
100 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateSitagliptin + Gatifloxacin
"Sitagliptin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSitagliptin + Rosoxacin
"Sitagliptin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSitagliptin + Levofloxacin
"Sitagliptin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateSitagliptin + Trovafloxacin
"Sitagliptin may increase the hypoglycemic activities of Trovafloxacin."
Linagliptin: 12 h (terminal, steady-state) with once-daily dosing providing sustained DPP-4 inhibition. Metformin: 6.2 h (terminal elimination) in patients with normal renal function; prolonged in renal impairment, contraindicated if eGFR < 30 mL/min/1.73 m².
12.4 hours; supports once-daily dosing with effect ≥24 h due to sustained DPP-4 inhibition.
Linagliptin: ~90% excreted unchanged in feces via enterohepatic recycling, <5% renally eliminated. Metformin: ~90% eliminated unchanged in urine via glomerular filtration and tubular secretion, <10% in feces.
Renal: ~87% unchanged in urine (active tubular secretion); fecal: <13% (metabolites).
Category C
Category A/B
DPP-4 Inhibitor / Biguanide Combination
DPP-4 Inhibitor